22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1564 787 50% 973 -590 930 -634
ERLYTX 76 78 103% 96 20 94 18
GI 479 162 34% 200 -278 196 -283
GU 450 364 81% 450 0 447 -3
GYN 57 0 0% 0 -57 0 -57
LEUK 150 110 73% 136 -13 127 -23
LUNG 524 127 24% 157 -366 279 -245
LYMPH 172 327 190% 404 232 377 205
MELAN 55 274 498% 339 284 353 298
MMYEL 147 127 86% 157 10 208 61
MULT 0 10   12 12 10 10
OTHER 0 27   33 33 35 35
PREV 0 2   2 2 5 5
SXQOL 0 2   2 2 3 3
Total 3674 2397   2961 -709 3064 -610

22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 2   2 2 2 2
BREAST 43 0 0% 0 -43 0 -43
CCD 0 81   100 100 183 183
ERLYTX 0 9   11 11 10 10
GU 0 0   0 0 0 0
LEUK 69 551 799% 681 612 668 599
LUNG 43 245 570% 303 260 275 232
LYMPH 53 1 2% 1 -51 1 -52
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 27   33 33 31 31
PEOLC 0 93   115 115 96 96
PREV 0 156   193 193 273 273
SURV 0 13   16 16 14 14
SXQOL 888 443 50% 548 -339 593 -295
Total 1188 1621   2003 817 2146 958

22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 4   4 4 4 4
BREAST 1607 787 49% 973 -633 930 -677
CCD 0 81   100 100 183 183
ERLYTX 76 87 114% 107 31 104 28
GI 479 162 34% 200 -278 196 -283
GU 450 364 81% 450 0 447 -3
GYN 57 0 0% 0 -57 0 -57
LEUK 219 661 302% 817 598 795 576
LUNG 567 372 66% 460 -106 554 -13
LYMPH 225 328 146% 405 180 378 153
MELAN 55 274 498% 339 284 353 298
MMYEL 239 127 53% 157 -81 208 -31
MULT 0 10   12 12 10 10
OTHER 0 54   66 66 66 66
PEOLC 0 93   115 115 96 96
PREV 0 158   195 195 278 278
SURV 0 13   16 16 14 14
SXQOL 888 445 50% 550 -337 596 -292
Total 4862 4020   4966 109 5212 350

22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1018 484 48% 598 -419 569 -449
ERLYTX 76 42 55% 51 -24 52 -24
GI 421 116 28% 143 -277 147 -274
GU 375 312 83% 386 11 385 10
GYN 57 0 0% 0 -57 0 -57
LEUK 122 65 53% 80 -41 78 -44
LUNG 441 86 20% 106 -334 178 -263
LYMPH 129 209 162% 258 129 243 114
MELAN 55 172 313% 212 157 223 168
MMYEL 85 83 98% 102 17 128 43
MULT 0 4   4 4 4 4
OTHER 0 27   33 33 35 35
PREV 0 2   2 2 5 5
SXQOL 0 2   2 2 3 3
Total 2779 1604   1977 -797 2050 -729

22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 2   2 2 2 2
BREAST 16 0 0% 0 -16 0 -16
CCD 0 74   91 91 154 154
ERLYTX 0 9   11 11 10 10
GU 0 0   0 0 0 0
LEUK 69 244 354% 301 232 304 235
LUNG 30 148 493% 183 153 163 133
LYMPH 53 1 2% 1 -51 1 -52
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 26   32 32 30 30
PEOLC 0 62   76 76 65 65
PREV 0 155   191 191 272 272
SURV 0 13   16 16 14 14
SXQOL 750 304 41% 376 -373 408 -342
Total 1010 1038   1280 272 1423 413

22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
  0 4   4 4 4 4
BREAST 1034 484 47% 598 -435 569 -465
CCD 0 74   91 91 154 154
ERLYTX 76 51 67% 63 -12 62 -14
GI 421 116 28% 143 -277 147 -274
GU 375 312 83% 386 11 385 10
GYN 57 0 0% 0 -57 0 -57
LEUK 191 309 162% 382 191 382 191
LUNG 471 234 50% 289 -181 341 -130
LYMPH 182 210 115% 259 77 244 62
MELAN 55 172 313% 212 157 223 168
MMYEL 177 83 47% 102 -74 128 -49
MULT 0 4   4 4 4 4
OTHER 0 53   65 65 65 65
PEOLC 0 62   76 76 65 65
PREV 0 157   194 194 277 277
SURV 0 13   16 16 14 14
SXQOL 750 306 41% 378 -371 411 -339
Total 3789 2644   3262 -521 3475 -314

22-OCT-2025 6:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

81% of Calendar Year is Past

COMMITTEE Base Accrual
2010		 2025
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2025
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 781 1202% 966 901 920 855
CCD 0 81   100 100 183 183
ERLYTX 0 2   2 2 2 2
GI 81 60 74% 74 -6 69 -12
GU 215 239 111% 295 80 300 85
LEUK 0 34   42 42 41 41
LUNG 53 66 125% 81 28 76 23
LYMPH 7 67 957% 82 75 82 75
MELAN 0 0   0 0 0 0
MMYEL 0 119   147 147 194 194
OTHER 0 22   27 27 27 27
PEOLC 0 93   115 115 96 96
PREV 0 158   195 195 199 199
SURV 0 13   16 16 14 14
SXQOL 880 445 51% 550 -329 596 -284
Total 1301 2180   2692 1393 2799 1498

22-OCT-2025 6:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
    A032102 ALLIANCE     2      
    A072201 ALLIANCE     1      
    A092205 ALLIANCE     1      
    G0249 NRG     0      
BREAST II NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   7     Dec-2022 Temp Close
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1     May-2022 Temp Close
  III A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib ALLIANCE 06JAN2021:00:00:00   55   0.0  
    A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab ALLIANCE 03MAY2023:00:00:00   42   3.5  
    A012301 Breast, Early Stg, Tamoxifen ALLIANCE 05FEB2025:00:00:00   26   4.0  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   61   1.7  
    NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG 07JUN2021:00:00:00   30   1.3  
    NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG 31AUG2023:00:00:00   22   1.8  
    S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva SWOG 30OCT2023:00:00:00 23 253 960 16.2 May-2029
    S2212 Breast, TNBC, Neoadj Chemo + Pembro SWOG 21JUL2023:00:00:00 27 946 2400 58.7 Oct-2027
CCD III S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 87 429 498 5.3 Oct-2026
    S2417CD Colrec Surv, Follow-up w/ CTAC site SWOG 04AUG2025:00:00:00 2 1 654    
  OTHER A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4     Feb-2021 Temp Close
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54     Aug-2022 Temp Close
    EAQ221CD Breast, Metastatic, Imp. Adherence ECOG-ACRIN 31OCT2023:00:00:00   4   0.3  
    EAQ222CD CostCOM, Cancer Patients, OOP Cost Com ECOG-ACRIN 29FEB2024:00:00:00   27   2.2  
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 28AUG2015:00:00:00   9   0.2  
    EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib SWOG 06MAR2023:00:00:00 31 32 33 2.0 Oct-2025
  II-III S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo SWOG 02DEC2021:00:00:00 46 124 189 5.2 Oct-2026
  III AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult COG 08MAY2017:00:00:00   4   0.2  
  OTHER EAY191 ComboMATCH ECOG-ACRIN 06MAR2023:00:00:00   20   1.2  
GI II CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG 05JUN2023:00:00:00   4   0.0  
    EA2192 Panc, APOLLO ECOG-ACRIN 29APR2021:00:00:00   6   0.2  
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 70 44 54 0.5 May-2027
    S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo SWOG 04DEC2020:00:00:00   73 88   Temp Close
    S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs SWOG 14OCT2021:11:13:50 48 81 154 2.5 Mar-2028
  II-III EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab ECOG-ACRIN 17JAN2019:00:00:00   6   0.0  
    NRGGI008 Colon, Stg III, Adj Chemo NRG 10MAR2022:00:00:00   44   2.0  
    S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo SWOG 06MAY2024:00:00:00 17 63 224 6.0 Dec-2027
  III A021806 Pancreas, Perioperative vs Adjuvant Chemo ALLIANCE 01JUL2020:00:00:00   36   0.5  
    A022101 Colorectal, Metastatic, Ablative Tx ALLIANCE 10JAN2023:00:00:00   1   0.0  
    A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo ALLIANCE 11JAN2023:00:00:00   33   0.8  
    CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG 29FEB2024:00:00:00   8   0.7  
    EA2222 Colorectal, Stg II-III, Hep Art Infusion ECOG-ACRIN 19OCT2023:00:00:00   6   0.5  
    NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG 06MAR2019:00:00:00   1   0.0  
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   27   0.7  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   28   0.2  
    A031801 GU, mRCC, Cabozantinib ± Radium-223 ALLIANCE 13DEC2019:00:00:00   15   0.0  
    NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG 08DEC2021:00:00:00   19   0.3  
    NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG 30JUN2022:00:00:00   10   0.7  
    S2200 pRCC, Adv, Cabo ± Atezo SWOG 19SEP2022:00:00:00 37 34 200 0.5 > 15 Yrs
    S2210 Pros, High Risk, BRCA, Neoadj Carbo SWOG 14AUG2023:00:00:00 26 5 44 0.2 > 15 Yrs
    S2427 Blad, MIBC, RT + Pembrolizumab SWOG 04SEP2025:00:00:00 1 0 111    
  II-III A032103 Urothelial, All Stg, MRD-Based Adj Tx ALLIANCE 09JAN2024:00:00:00   28   2.3  
    EA8192 Blad, High Grade UTUC, Durv + Chemo ECOG-ACRIN 06MAY2021:00:00:00   6   0.3  
  III A032201 Renal Cell, High-Risk, Pembro+Tiv ALLIANCE 05FEB2025:00:00:00   2   0.3  
    CCTG-PR26 Prostate, Cast Sensitive, Docetax CCTG 30JAN2025:00:00:00   1   0.2  
    EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   21   1.0  
    EA8191 Pros, Local vs Systemic Thrpy ECOG-ACRIN 08OCT2020:00:00:00   66   0.2  
    NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG 05MAR2020:00:00:00   16   0.3  
    NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG 03NOV2021:00:00:00   65   0.5  
    NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG 13NOV2023:00:00:00   12   0.8  
    S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 85 961 1273 8.7 Sep-2028
    S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only SWOG 16NOV2020:00:00:00 59 138 336 2.3 Oct-2032
    S1937 Blad, Mets, Eribulin + Gem vs SOC SWOG 16FEB2021:00:00:00 56 114 184 5.0 Nov-2026
    S2312 Pros, MCRPC, Cab +/- Carb SWOG 03SEP2024:00:00:00 13 32 500 2.3 > 15 Yrs
LEUK I-II S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 SWOG 17AUG2020:00:00:00   24 67   Oct-2025 Temp Close
  II 21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone SWOG 15MAY2025:00:00:00 5 0 55 0.0 > 15 Yrs
    A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat ALLIANCE 16NOV2018:00:00:00   5   0.0  
    EA9213 T-ALL, dara-hyal for chemo refractory MRD ECOG-ACRIN 16JUN2022:00:00:00   3   0.0  
    MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena SWOG 01APR2025:00:00:00   8 102   Oct-2025 Temp Close
    MM1OAEA02 MyeloMATCH: AML, New Dx, Ven+HMA ECOG-ACRIN 06JUN2024:00:00:00   9   1.0  
    MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental SWOG 16MAY2024:00:00:00 17 45 335 5.2 Jun-2030
    MM1YACTG01 MyeloMATCH: AML, New/Young/Int, Ven+Chemo CCTG 18JUL2024:00:00:00   5   0.5  
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   44   0.0  
    EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab ECOG-ACRIN 14OCT2020:00:00:00   49   1.0  
    S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O SWOG 14DEC2020:00:00:00 58 160 247 3.3 Dec-2027
  OTHER MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials SWOG 16MAY2024:00:00:00 17 748   52.8  
LUNG II EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 ECOG-ACRIN 05APR2018:00:00:00   4   0.2  
    S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu SWOG 03APR2023:00:00:00 30 22 66 0.5 Jan-2033
    S1900J MET Amplification: Amivantamab Hyaluronidase SWOG 27SEP2024:10:59:58 12 3 88 0.2 > 15 Yrs
    S1900K MET Exon 14: Tepotinib +/- Ramucirumab SWOG 18DEC2023:00:00:00 22 14 56 1.5 Jan-2028
    S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 64 47 47 0.7 Oct-2025
    S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx SWOG 08SEP2025:00:00:00 1 0 900    
  II-III A082002 Lung, Adv, Systemic Tx +/- SBRT ALLIANCE 21DEC2021:00:00:00   4   0.0  
    S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab SWOG 28APR2025:10:50:48 5 26 378 4.5 Apr-2032
  III A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO ALLIANCE 03JUN2020:00:00:00   99   1.5  
    EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 ECOG-ACRIN 22OCT2020:00:00:00   25   0.5  
    EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno ECOG-ACRIN 15FEB2024:00:00:00   3   0.2  
    NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG 10MAY2023:00:00:00   5   0.5  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 69 296 668 3.8 Nov-2033
    S2402 NSCLC, All Stg, Periop Vs Adj Tx ALLIANCE 11DEC2024:00:00:00   4   0.7  
    S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance SWOG 14MAR2025:00:00:00 7 4 306 0.5 > 15 Yrs
  OTHER LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 80 3786   29.3  
LYMPH II A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P ALLIANCE 30JUL2021:00:00:00   19   0.7  
    S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation SWOG 23FEB2023:11:55:36 31 168 396 7.3 May-2028
    S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa SWOG 30JUN2023:11:49:39   34 241   Oct-2025 Temp Close
  II-III S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP SWOG 19MAR2021:00:00:00   136 422   Apr-2025 Temp Close
  III A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub ALLIANCE 08SEP2023:00:00:00   23   1.0  
    AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy COG 28APR2023:00:00:00   71   3.7  
    EA4232 Lymph, Peri T Cell, Auto Stem ECOG-ACRIN 30JAN2025:00:00:00   1   0.2  
    S2308 FL, LTB, Mosunetuzumab vs Rituximab SWOG 01AUG2024:00:00:00 14 194 600 20.5 May-2027
MELAN II A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo ALLIANCE 01JUN2022:00:00:00   1   0.0  
  II-III EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 10SEP2015:00:00:00   76   1.0  
MMYEL II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   39   0.3  
    S2005 WM, Prev. Untreated, I/R +/- Venetoclax SWOG 24JUN2021:00:00:00 51 20 92 1.3 Mar-2030
  III EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) ECOG-ACRIN 27OCT2020:00:00:00   45   1.0  
    S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 75 1338 1100 0.5 Mar-1986
    S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D SWOG 30MAY2023:00:00:00 28 103 510 4.5 Apr-2033
    S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT SWOG 01DEC2023:00:00:00 22 26 338 2.5 Feb-2036
MMYL II A062102 MMYL, All Stg, Iberdomide Tx ALLIANCE 04APR2024:00:00:00   0   0.0  
MULT II S2101 Melan or HNSCC, Adv, Cabo + Nivo SWOG 14OCT2022:10:48:23 36 64 220 1.7 Jul-2033
OTHER I NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG 18NOV2019:00:00:00   3   0.0  
  II A071701 BRAIN, Met, Geno-guided trial ALLIANCE 15AUG2019:00:00:00   2   0.0  
    A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab ALLIANCE 18SEP2023:00:00:00   1   0.2  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   22   0.0  
    EA3191 HN, High Risk HNSCC, Adj +/- Pembro ECOG-ACRIN 08JAN2021:00:00:00   13   0.0  
    NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG 16APR2024:00:00:00   1   0.2  
    NRGHN010 HER2+ SGC, T-DM1 vs TH NRG 30SEP2022:00:00:00   4   0.0  
  II-III NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG 12AUG2022:00:00:00   3   0.3  
    NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG 08JUL2020:00:00:00   3   0.0  
    NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG 27OCT2021:00:00:00   19   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   7   0.0  
  III AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   5     Temp Close
    CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG 29SEP2022:00:00:00   1   0.0  
    CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy CCTG 25MAY2018:00:00:00   1   0.0  
    EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox ECOG-ACRIN 13JUN2024:00:00:00   9   1.2  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.0  
    NRGBN011 Brain, Lomustine + Temo vs Temo NRG 29NOV2021:00:00:00   15   0.7  
    NRGBN013 Brain, Intact Metas, SRS vs FSRS NRG 28AUG2024:00:00:00   5   0.7  
    NRGCC014 High Risk, Bone Meta, Radiation Tx NRG 14APR2025:00:00:00   12   2.0  
    NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG 16JAN2025:00:00:00   2   0.3  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   48   1.3  
PEOLC III S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 97 378 491 7.0 Feb-2027
    S2408 Panc Fistula Prevention, Lanreotide SWOG 14FEB2025:00:00:00 8 28 274 4.7 Feb-2030
PREV II EA2185 Panc, Impact of Panc Cyst Surveillance ECOG-ACRIN 16JAN2020:00:00:00   20   0.2  
  III NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG 06OCT2021:00:00:00   110   8.5  
  OTHER A212102 Blind Ref Set for Multicancer Early Detection ALLIANCE 01AUG2022:00:00:00   253   8.0  
    NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG 23JUN2020:00:00:00   13   0.3  
SURV OTHER EAQ211 Lymph, Survivors, Health Disp. AYA ECOG-ACRIN 30AUG2023:00:00:00   14   1.8  
SXQOL III A211901 Cancer survivors who smoke, txt cessation ALLIANCE 01DEC2021:00:00:00   15   0.3  
    A222004 Mult, Olanza vs Megestrol for Anorexia ALLIANCE 15OCT2021:00:00:00   7   0.0  
    ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis COG 14AUG2023:00:00:00   6   0.3  
    NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG 19SEP2022:00:00:00   15   0.3  
    NRGCC011 Breast, Survivors, Cog Training NRG 02FEB2024:00:00:00   37   0.7  
    NRGCC015 E-Mindfulness After Breast Cancer NRG 12JUN2025:00:00:00   0   0.0  
    S2205 ICE COMPRESS: Reduction of CIPN from Taxanes SWOG 16MAR2023:00:00:00 31 474 777 22.0 Nov-2026
  OTHER S2013 I-CHECKIT: ICI toxicity risk prediction study SWOG 16AUG2021:00:00:00 50 2306 3609 20.5 Jan-2031
  PILOT EAQ202 Improving AYA PROs in EA Trials ECOG-ACRIN 28OCT2021:00:00:00   43   0.0  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

22-OCT-2025 6:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
OTHER CCD     EAQ221CD Breast, Metastatic, Imp. Adherence   Y  
        EAQ222CD CostCOM, Cancer Patients, OOP Cost Com   Y  
    Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y Y
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD Y Y
  ERLYTX Y ECOG-ACRIN EAY191 ComboMATCH EAY191 N  
  LEUK Y SWOG MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials MYELOMATCH N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
  PREV Y ALLIANCE A212102 Blind Ref Set for Multicancer Early Detection A212102 Y  
    Y NRG NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO NRG-CC008 Y  
  SURV Y ECOG-ACRIN EAQ211 Lymph, Survivors, Health Disp. AYA EAQ211 Y  
  SXQOL Y SWOG S2013 I-CHECKIT: ICI toxicity risk prediction study S2013 Y  
I OTHER Y NRG NRGGY022 Mult Site/Stg, Carboplat Clearance Predict NRG-GY022 N  
I-II LEUK Y SWOG S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 S1905 N Y
II BREAST Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N Y
  ERLYTX Y SWOG EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib EAY191-S3 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI     EA2192 Panc, APOLLO   N  
    Y SWOG S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo S2001 N Y
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y SWOG S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs S2104 N  
    Y CCTG CCTGNE1 Midgut NET, Unresect, 177 Lut vs Ever CCTG-NE1 Y  
  GU Y SWOG S2200 pRCC, Adv, Cabo ± Atezo S2200 N  
    Y SWOG S2427 Blad, MIBC, RT + Pembrolizumab S2427 N  
    Y SWOG S2210 Pros, High Risk, BRCA, Neoadj Carbo S2210 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y NRG NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx NRG-GU011 Y  
    Y NRG NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy NRG-GU012 N  
    Y ALLIANCE A031801 GU, mRCC, Cabozantinib ± Radium-223 A031801 Y  
  LEUK N   21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone   N  
        EA9213 T-ALL, dara-hyal for chemo refractory MRD   N  
    Y SWOG MM1OA-S03 AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena MM1OA-S03 N Y
    Y SWOG MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental MM1YA-S01 N  
    Y ECOG-ACRIN MM1OAEA02 MyeloMATCH: AML, New Dx, Ven+HMA MM1OA-EA02 N  
    Y ALLIANCE A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat A041703 N  
    Y CCTG MM1YACTG01 MyeloMATCH: AML, New/Young/Int, Ven+Chemo MM1YA-CTG01 N  
  LUNG Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
    Y SWOG S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu S1900G N  
    Y SWOG S1900K MET Exon 14: Tepotinib +/- Ramucirumab S1900K N  
    Y SWOG S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx S2409 N  
    Y SWOG S1900J MET Amplification: Amivantamab Hyaluronidase S1900J N  
    Y ECOG-ACRIN EA5162 NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 EA5162 N  
  LYMPH Y SWOG S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa S2207 Y Y
    Y SWOG S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation S2114 N  
    Y ALLIANCE A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P A051902 N  
  MELAN     A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo   N  
  MMYEL Y SWOG S2005 WM, Prev. Untreated, I/R +/- Venetoclax S2005 N  
    Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  MMYL     A062102 MMYL, All Stg, Iberdomide Tx   N  
  MULT Y SWOG S2101 Melan or HNSCC, Adv, Cabo + Nivo S2101 N  
  OTHER Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y NRG NRGHN010 HER2+ SGC, T-DM1 vs TH NRG-HN010 N  
    Y ALLIANCE A071701 BRAIN, Met, Geno-guided trial A071701 N  
    Y NRG NRGGY032 Endo, ErlyStg Pole/p53, Adj Tx NRG-GY032 N  
    Y ECOG-ACRIN EA3191 HN, High Risk HNSCC, Adj +/- Pembro EA3191 N  
    Y ALLIANCE A092105 Nasopharyngeal, Adv, Niv/Ip +- Cab A092105 N  
  PREV Y ECOG-ACRIN EA2185 Panc, Impact of Panc Cyst Surveillance EA2185 Y  
PILOT SXQOL Y ECOG-ACRIN EAQ202 Improving AYA PROs in EA Trials EAQ202 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N Y
  ERLYTX Y SWOG S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo S2012 N  
  GI Y SWOG S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo S2303 Y  
    Y ECOG-ACRIN EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab EA2174 N  
    Y NRG NRGGI008 Colon, Stg III, Adj Chemo NRG-GI008 N  
  GU     A032103 Urothelial, All Stg, MRD-Based Adj Tx   Y  
    Y ECOG-ACRIN EA8192 Blad, High Grade UTUC, Durv + Chemo EA8192 N  
  LUNG Y SWOG S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab S1800E N  
    Y ALLIANCE A082002 Lung, Adv, Systemic Tx +/- SBRT A082002 Y  
  LYMPH Y SWOG S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP S1918 Y Y
  MELAN Y ECOG-ACRIN EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN006 HN, Erly Stg, Biopsy vs Dissection NRG-HN006 Y  
    Y NRG NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN NRG-HN009 Y  
    Y NRG NRGGY026 Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE NRG-GY026 Y  
III BREAST Y SWOG S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva S2206 Y  
    Y SWOG S2212 Breast, TNBC, Neoadj Chemo + Pembro S2212 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
    Y ALLIANCE A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib A011801 Y  
    Y ALLIANCE A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab A012103 Y  
    Y NRG NRGBR009 Breast, EarlyStg, Adjuvant Chemo NRG-BR009 Y  
    Y ALLIANCE A012301 Breast, Early Stg, Tamoxifen A012301 Y  
    Y NRG NRGBR007 Breast, Stg I, De-Escalation of Breast RT NRG-BR007 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y SWOG S2417CD Colrec Surv, Follow-up w/ CTAC site S2417CD Y  
  ERLYTX Y COG AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult AGCT1531 Y  
  GI     A022101 Colorectal, Metastatic, Ablative Tx   N  
    Y NRG NRGGI006 Esophagus, Stg I-IVA, PBT vs IMRT NRG-GI006 Y  
    Y CCTG CCTGCO32 Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad CCTG-CO32 Y  
    Y ECOG-ACRIN EA2222 Colorectal, Stg II-III, Hep Art Infusion EA2222 N  
    Y ALLIANCE A021806 Pancreas, Perioperative vs Adjuvant Chemo A021806 Y  
    Y ALLIANCE A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo A022102 N  
  GU N   S2312 Pros, MCRPC, Cab +/- Carb   N  
    Y SWOG S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1937 Blad, Mets, Eribulin + Gem vs SOC S1937 N  
    Y SWOG S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only S1931 N  
    Y ALLIANCE A032201 Renal Cell, High-Risk, Pembro+Tiv A032201 Y  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y NRG NRGGU013 Prostate, High-Risk, Five Fraction Radiation NRG-GU013 Y  
    Y NRG NRGGU010 Pros, Parallel De-Intens & Intens Trials NRG-GU010 Y  
    Y ECOG-ACRIN EA8191 Pros, Local vs Systemic Thrpy EA8191 Y  
    Y NRG NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide NRG-GU008 Y  
    Y CCTG CCTG-PR26 Prostate, Cast Sensitive, Docetax CCTG-PR26 N  
  LEUK Y SWOG S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O S1925 Y  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
    Y ECOG-ACRIN EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab EA9181 N  
  LUNG     EA5221 Lung, Advanced NSCLC, ChemoImmuno/Immuno   Y  
    Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance S2414 Y  
    Y NRG NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo NRG-LU008 Y  
    Y ALLIANCE A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO A081801 Y  
    Y ECOG-ACRIN EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 EA5182 N  
    Y ALLIANCE S2402 NSCLC, All Stg, Periop Vs Adj Tx CTIU2317-A082304-S2402 N  
  LYMPH Y SWOG S2308 FL, LTB, Mosunetuzumab vs Rituximab S2308 N  
    Y ALLIANCE A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub A052101 Y  
    Y ECOG-ACRIN EA4232 Lymph, Peri T Cell, Auto Stem EA4232 N  
    Y COG AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy AHOD2131 Y  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 Y  
    Y SWOG S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D S2209 Y  
    Y SWOG S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT S2213 Y  
    Y ECOG-ACRIN EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) EAA181 Y  
  OTHER     CE7 Brain, 5+ Metastases, Radiosurg/Radiotherapy   Y  
    Y NRG NRGGY036 Ovary, All Stg, Olaparib +/- Bevac NRG-GY036 N  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y Y
    Y CCTG CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx CCTG-HN11 Y  
    Y NRG NRGCC014 High Risk, Bone Meta, Radiation Tx NRG-CC014 Y  
    Y NRG NRGBN011 Brain, Lomustine + Temo vs Temo NRG-BN011 Y  
    Y NRG NRGBN013 Brain, Intact Metas, SRS vs FSRS NRG-BN013 N  
    Y ECOG-ACRIN EA7222 Sarcoma, Poorly Diff, Dox+Pembro vs Dox EA7222 N  
  PEOLC Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y SWOG S2408 Panc Fistula Prevention, Lanreotide S2408 Y  
  PREV Y NRG NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs NRG-CC005 Y  
  SXQOL     NRGCC011 Breast, Survivors, Cog Training   Y  
        NRGCC015 E-Mindfulness After Breast Cancer   Y  
    Y SWOG S2205 ICE COMPRESS: Reduction of CIPN from Taxanes S2205 Y  
    Y ALLIANCE A211901 Cancer survivors who smoke, txt cessation A211901 Y  
    Y COG ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis ACCL1931 Y  
    Y ALLIANCE A222004 Mult, Olanza vs Megestrol for Anorexia A222004 Y  
    Y NRG NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction NRG-CC010 Y  
        A032102      
    Y ALLIANCE A072201 A072201    
    Y ALLIANCE A092205 A092205    
    Y NRG G0249 GOG-0249    

22-OCT-2025 6:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (PEOLC) 491 Y-09/15/17 97 378 378 84 Feb-2027 9.4
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 498 Y-07/16/18 87 429 429 64 Oct-2026 8.3
S1800E S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab (LUNG) 378 Y-04/28/25 5 26 26 53.7914 Apr-2032 7.0
S1802 S1802 Pros, Stg IV, SST ± Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 85 961 961 104 Sep-2028 10.0
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 75 1338 1338 6 Mar-1986 -33.3
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 69 296 296 46 Nov-2033 13.9
S1918 S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) 422 T-03/19/21 55 136 136 0 > 15 Yrs > 15 Yrs
S1925 S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) 247 Y-12/14/20 58 160 160 40 Dec-2027 7.0
S1931 S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) 336 Y-11/16/20 59 138 138 28 Oct-2032 11.9
S1937 S1937 Blad, Mets, Eribulin + Gem vs SOC (GU) 184 Y-02/16/21 56 114 114 60 Nov-2026 5.8
S2012 S2012 Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) 189 Y-12/02/21 46 124 124 62 Oct-2026 4.9
S2205 S2205 ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL) 777 Y-03/16/23 31 474 474 264 Nov-2026 3.7
S2206 S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST) 960 Y-10/30/23 23 253 253 194 May-2029 5.6
S2209 S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL) 510 Y-05/30/23 28 103 103 54 Apr-2033 9.9
S2212 S2212 Breast, TNBC, Neoadj Chemo + Pembro (BREAST) 2400 Y-07/21/23 27 946 946 704 Oct-2027 4.3
S2213 S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT (MMYEL) 338 Y-12/01/23 22 26 26 30 Feb-2036 12.2
S2303 S2303 Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo (GI) 224 Y-05/06/24 17 63 63 72 Dec-2027 3.6
S2308 S2308 FL, LTB, Mosunetuzumab vs Rituximab (LYMPH) 600 Y-08/01/24 14 194 194 246 May-2027 2.8
S2312 Pros, MCRPC, Cab +/- Carb (GU) 500 Y-09/03/24 13 32 32 28 > 15 Yrs > 15 Yrs
S2408 S2408 Panc Fistula Prevention, Lanreotide (PEOLC) 274 Y-02/14/25 8 28 28 56 Feb-2030 5.0
S2414 S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance (LUNG) 306 Y-03/14/25 7 4 4 6 > 15 Yrs > 15 Yrs
S2417CD S2417CD Colrec Surv, Follow-up w/ CTAC site (CCD) 654 Y-08/04/25 2 1 1      
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.